Form 4: Serina Therapeutics CSO Sells Shares Under 10b5-1 Plan

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 949 shares of common stock after exercising options under a pre-arranged trading plan.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., reported transactions involving company stock.
• Moreadith exercised stock options to acquire 949 shares of common stock at an exercise price of $0.06 per share on October 27, 2025.
• Immediately following the exercise, 949 shares of common stock were sold at a weighted average price of $5.1857 per share on October 27, 2025.
• The sales occurred in multiple transactions with prices ranging from $5.10 to $5.25 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• After these transactions, Moreadith beneficially owns 409,737 stock options, which are fully vested.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of common stock under a pre-arranged 10b5-1 trading plan. This type of transaction is generally considered neutral for company sentiment, as it reflects personal financial management rather than a reaction to specific company performance or outlook.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to immediate company news, which can mitigate negative market perception.
• The exercise price of $0.06 and sale price of $5.1857 demonstrate a significant profit for the insider on these specific shares.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's personal financial planning.

Comparison to Industry Standards

• This filing reports an insider transaction, which is a standard disclosure requirement across all publicly traded companies.
• There are no specific company or project results to compare against industry benchmarks in this document. The transaction itself is a common occurrence for executives managing their equity compensation.

Stakeholder Impact

• Shareholders: May view the insider sale as a slight negative, though mitigated by the 10b5-1 plan and the insider's continued significant option holdings.
• Management: Randall Moreadith has reduced his direct common stock holdings but retains substantial unexercised option holdings.

Key Dates

Recommendation

The filing details a routine insider transaction where the Chief Scientific Officer exercised stock options and sold the resulting shares under a pre-arranged 10b5-1 plan. While the sale reduces the insider's direct equity stake, the pre-planned nature suggests it's for personal financial management rather than a reaction to new company-specific information. The insider still retains a substantial number of unexercised options. Without additional company-specific news or financial updates, this transaction alone does not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Serina Therapeutics, SER, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan